Literature DB >> 32108197

High aldehyde dehydrogenase activity does not protect colon cancer cells against TPCS2a-sensitized photokilling.

Judith Jing Wen Wong1, Pål Kristian Selbo1.   

Abstract

Aldehyde dehydrogenases (ALDH) are detoxifying enzymes that are upregulated in cancer stem cells (CSCs) and may cause chemo- and ionizing radiation (IR) therapy resistance. By using the ALDEFLUOR assay, CD133 + human colon cancer cells HT-29, were FACSorted into three populations: ALDHbright, ALDHdim and unsorted (bulk) and treated with chemo-, radio- or photodynamic therapy (PDT) using the clinical relevant photosensitizer disulfonated tetraphenyl chlorin (TPCS2a/fimaporfin). Here we show that there is no difference in cytotoxic responses to TPCS2a-PDT in ALHDbright, ALDHdim or bulk cancer cells. Likewise, both 5-FU and oxaliplatin chemotherapy efficacy was not reduced in ALDHbright as compared to ALDHdim cancer cells. However, we found that ALHDbright HT-29 cells are significantly less sensitive to ionizing radiation compared to ALDHdim cells. This study demonstrates that the cytotoxic response to PDT (using TPCS2a as photosensitizer) is independent of ALDH activity in HT-29 cancer cells. Our results further strengthen the use of TPCS2a to target CSCs.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32108197     DOI: 10.1039/c9pp00453j

Source DB:  PubMed          Journal:  Photochem Photobiol Sci        ISSN: 1474-905X            Impact factor:   3.982


  6 in total

Review 1.  Photodynamic therapy of cancer: an update.

Authors:  Patrizia Agostinis; Kristian Berg; Keith A Cengel; Thomas H Foster; Albert W Girotti; Sandra O Gollnick; Stephen M Hahn; Michael R Hamblin; Asta Juzeniene; David Kessel; Mladen Korbelik; Johan Moan; Pawel Mroz; Dominika Nowis; Jacques Piette; Brian C Wilson; Jakub Golab
Journal:  CA Cancer J Clin       Date:  2011-05-26       Impact factor: 508.702

2.  Strongly amphiphilic photosensitizers are not substrates of the cancer stem cell marker ABCG2 and provides specific and efficient light-triggered drug delivery of an EGFR-targeted cytotoxic drug.

Authors:  Pål Kristian Selbo; Anette Weyergang; Marius Strømbo Eng; Monica Bostad; Gunhild M Mælandsmo; Anders Høgset; Kristian Berg
Journal:  J Control Release       Date:  2012-02-10       Impact factor: 9.776

3.  Selection of radioresistant tumor cells and presence of ALDH1 activity in vitro.

Authors:  Julia Mihatsch; Mahmoud Toulany; Petra M Bareiss; Sabrina Grimm; Claudia Lengerke; Rainer Kehlbach; H Peter Rodemann
Journal:  Radiother Oncol       Date:  2011-06-23       Impact factor: 6.280

4.  Aldehyde Dehydrogenase Is Regulated by β-Catenin/TCF and Promotes Radioresistance in Prostate Cancer Progenitor Cells.

Authors:  Monica Cojoc; Claudia Peitzsch; Ina Kurth; Franziska Trautmann; Leoni A Kunz-Schughart; Gennady D Telegeev; Eduard A Stakhovsky; John R Walker; Karl Simin; Stephen Lyle; Susanne Fuessel; Kati Erdmann; Manfred P Wirth; Mechthild Krause; Michael Baumann; Anna Dubrovska
Journal:  Cancer Res       Date:  2015-02-10       Impact factor: 12.701

5.  Colon cancer cells escape 5FU chemotherapy-induced cell death by entering stemness and quiescence associated with the c-Yes/YAP axis.

Authors:  Yasmine Touil; Wassila Igoudjil; Matthieu Corvaisier; Anne-Frédérique Dessein; Jérôme Vandomme; Didier Monté; Laurence Stechly; Nicolas Skrypek; Carole Langlois; Georges Grard; Guillaume Millet; Emmanuelle Leteurtre; Patrick Dumont; Stéphanie Truant; François-René Pruvot; Mohamed Hebbar; Fan Fan; Lee M Ellis; Pierre Formstecher; Isabelle Van Seuningen; Christian Gespach; Renata Polakowska; Guillemette Huet
Journal:  Clin Cancer Res       Date:  2013-12-09       Impact factor: 12.531

6.  Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition.

Authors:  Nikolaos A Dallas; Ling Xia; Fan Fan; Michael J Gray; Puja Gaur; George van Buren; Shaija Samuel; Michael P Kim; Sherry J Lim; Lee M Ellis
Journal:  Cancer Res       Date:  2009-02-24       Impact factor: 12.701

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.